Accelerating Oncology Trials
Dr. Oliver Overheu, Senior Associate, Duke Capital Partners
Oncology clinical trials remain the bottleneck in oncology drug development. They are often slowed by complex design, recruitment challenges, and regulatory requirements. By integrating patient-centric strategies, digital innovations, and collaborative trial models while navigating evolving FDA frameworks, oncology trials can deliver innovative therapies to patients faster, safer, and more efficiently.
1. Oncology trials are widely acknowledged as the bottleneck in cancer drug development. From your perspective, what are the root systemic inefficiencies that make oncology trials uniquely challenging compared to other therapeutic areas?
No two cancers are alike, each entity is basically a separate disease, and oncology has moved far beyond the era of one-size-fits-all medicine. Each clinical trial must navigate complex eligibility criteria, biomarker-driven subgroups, and stringent regulatory oversight. Protocols are lengthy, and long follow-up periods demand intensive safety monitoring. Together, these factors create structural inefficiencies – slowing innovation, inflating development costs, and delaying patient access to life-saving therapies.
2. Patient recruitment remains a persistent hurdle. How can patient-centric trial designs and engagement strategies not only improve recruitment rates but also enhance long-term retention in oncology studies?
Recruitment in oncology often falters because eligibility criteria fragment patient populations and trial participation imposes heavy logistical and emotional burdens. Patient-centric trial designs that integrate local care networks, telehealth visits, and digital engagement tools transform participation from a burden into a partnership and are important tools to increase trial access. By aligning trial design with patient needs, oncology studies enhance recruitment rates and foster long-term retention, leading to more reliable outcomes and faster development timelines.
3. Digital innovations such as remote monitoring, AI-driven site selection, and adaptive trial platforms are becoming central to clinical research. Which of these technologies holds the greatest promise for accelerating oncology trials, and why?
Remote monitoring technologies hold transformative potential for oncology trials by expanding access beyond major academic centers. Patients in rural or underserved regions can participate without repeated long-distance travel, improving important recruitment diversity and retention. Integrated digital monitoring ensures continuous safety oversight, while adaptive trial platforms allow real-time data to guide protocol adjustments, combining inclusivity with accelerated development timelines.
4. Decentralised and hybrid trial models are gaining traction. In the oncology space - where treatments are complex and safety monitoring is critical - what adaptations are required to ensure these models remain both feasible and safe?
Decentralised and hybrid models can meaningfully accelerate oncology trials when adapted to the clinical complexity of cancer care. Hybrid frameworks that pair community-based treatment sites with tele-oncology monitoring reduce travel and broaden patient reach. Continuous digital safety tracking and real-time adverse-event alerts preserve oversight, while standardised workflows and regulatory-grade data capture ensure feasibility and patient safety across distributed networks.
5. With oncology trials often involving highly targeted patient subgroups, how do you see real-world evidence (RWE) and big data analytics shaping recruitment, protocol design, and regulatory acceptance?
The molecular fragmentation of modern oncology has dramatically reduced eligible trial populations, making patient recruitment slower and more resource-intensive. Real-world evidence can mitigate this constraint by serving as external or hybrid control arms, reducing the number of patients required for randomisation and expediting enrollment. Robust data curation and big-data analytics enable precise patient matching and bias adjustment, ensuring statistical validity. When appropriate frameworks are developed together with regulators, development timelines shorten without compromising evidentiary rigor.
6. Collaboration between academic institutions, industry sponsors, and regulatory bodies is increasingly emphasised. What are the most effective models of collaboration you’ve observed, and how do they directly impact trial acceleration?
The most effective collaboration models in oncology pair academic innovation with industry execution and regulatory insight from the earliest stages. Tight, trust-based networks between academia and industry enable the translation of promising discoveries from concept to clinical testing. Transparent collaboration and aligned incentives ensure that translational findings rapidly evolve into viable therapeutic programs. Early regulatory engagement streamlines approval pathways, while data-sharing frameworks between institutions and sponsors shorten feedback cycles, improve resource utilisation, and translate discovery into patient benefit faster.
7. The FDA’s evolving frameworks - such as accelerated approvals and real-time oncology review - are reshaping trial design. How should sponsors adapt to these evolving regulatory landscapes without compromising data integrity?
Accelerated approval pathways have helped bring innovative oncology therapeutics to patients faster. Yet these mechanisms demand tight, ongoing interaction with regulators, especially as the FDA has increased scrutiny on surrogate endpoints and confirmatory evidence. Sponsors that embed regulatory strategy early – validating endpoints, planning adaptive designs, and maintaining continuous data readiness – can meet this higher bar. Proactive engagement and transparent communication with agencies preserve data integrity while ensuring speed translates into safe, durable patient benefit.
8. Oncology trials frequently involve complex endpoints beyond survival, such as quality of life and biomarker-driven outcomes. How can innovative trial designs balance scientific rigor with patient relevance?
Traditional survival endpoints remain vital in oncology, but they sometimes fail to capture what patients value most. Modern trial designs should integrate patient-reported outcomes, quality-of-life measures, and biomarker-based efficacy signals into composite endpoint frameworks. Adaptive methodologies allow these measures to evolve as data mature, maintaining statistical integrity while reflecting what truly matters to patients. This alignment of scientific rigor and patient relevance yields evidence that regulators trust and patients value, accelerating both approval and adoption.
9. Given the rapid evolution of personalised medicine and biomarker-based therapies, what shifts are required in trial infrastructure to accommodate smaller, more precise patient cohorts?
Personalised oncology has fragmented trial populations into smaller, molecularly defined cohorts that come with unique logistical hurdles. Integrated testing and biobanks help identify eligible patients quickly and consistently across sites. Flexible trial platforms – such as basket and umbrella studies – reduce redundancy by utilising shared infrastructures. Trial systems must also be built for regulatory readiness, supporting adaptive designs and rolling submissions. Finally, strong industry–academic partnerships expand access to rare patient populations and accelerate translation into clinical impact.
10. Digital platforms promise efficiency, but they also introduce challenges around data privacy, interoperability, and standardisation. How should stakeholders navigate these competing priorities in oncology trials?
Digital platforms are now central to oncology research, yet their success depends on balancing efficiency with data responsibility. Robust privacy safeguards, harmonized standards, and interoperable systems protect patients while enabling collaboration across sponsors, regulators, and research sites. Clear governance frameworks that define ownership, consent, and access create trusted ecosystems where digital innovation aligns with ethical and regulatory compliance.
11. From a business and strategic perspective, how do accelerated oncology trials influence the broader economics of drug development and the sustainability of innovation pipelines?
Accelerated oncology trials compress time-to-market and lower development costs, reshaping the economics of drug development. Yet recent regulatory scrutiny of accelerated approvals has introduced uncertainty that can deter early-stage investment. Predictable, transparent frameworks are critical to sustaining high-risk innovation. When regulatory clarity and robust post-approval commitments align, accelerated pathways enhance capital efficiency and reinvestment – creating a sustainable model where financial performance and continuous innovation reinforce one another, ultimately improving patient access to breakthrough therapies.
12. Globalisation of oncology trials introduces both opportunities and challenges. How do regional regulatory differences, cultural patient factors, and infrastructure gaps affect the feasibility of scaling accelerated trial models worldwide?
Global oncology trials offer access to diverse patient populations but face significant disparities in regulation, infrastructure, and patient engagement. Differing approval standards and ethics frameworks extend timelines, while uneven access to diagnostics and trial infrastructure limits participation in emerging regions. Overcoming these barriers requires harmonised regulatory frameworks and alignment on quality standards. When global trial networks coordinate around these principles, acceleration becomes both feasible and equitable, broadening worldwide access for patients to oncology innovation.
13. As oncology drugs increasingly integrate with companion diagnostics, how should trial designs evolve to test therapies and diagnostics in tandem while keeping timelines efficient?
Companion diagnostics have become integral to targeted oncology therapy, requiring trial designs that evaluate drugs and assays together from the outset. Early alignment between therapeutic and diagnostic development avoids sequential validation that slows progress. Adaptive platform trials and standardised biomarker assays enable concurrent testing of multiple targets under a single protocol, maintaining efficiency and scientific rigor. Close collaboration between sponsors, regulators, and diagnostic partners ensures synchronised approvals and delivers precision therapies to patients faster.
14. Looking ahead, what is your vision of an “ideal” oncology trial ecosystem in the next decade - one that is both patient-centric and innovation-driven? What milestones need to be achieved to make that vision a reality?
The ideal oncology trial ecosystem will be decentralised, data-driven, and genuinely patient-centric. Participation will no longer depend on geography, as digital platforms, interoperable data systems, and remote monitoring enable global inclusion. Regulatory frameworks must evolve to recognise real-world and digital evidence as complementary to traditional endpoints, creating pathways for faster, evidence-based approvals. True acceleration will come from a culture of collaboration—where academia, industry, regulators, and patients co-create solutions that turn scientific innovation into timely, equitable access to care.
Author Bio
Oliver Overheu, MD, is a board-certified oncologist, an MBA candidate at Duke University’s Fuqua School of Business, and an Associate at Duke Capital Partners. His background, beyond clinical practice, spans oncology research, clinical development, and biopharmaceutical strategy. By combining medical, business, and investment expertise, he helps bring new therapies to market through trial design, regulatory navigation, and patient-focused strategies.
